Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

79.75EUR
12:04pm BST
Price Change (% chg)

€-1.50 (-1.85%)
Prev Close
€81.25
Open
€81.04
Day's High
€81.20
Day's Low
€79.67
Volume
1,249,682
Avg. Vol
3,050,290
52-wk High
€89.95
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.58
Market Cap (Mil.): €107,816.80
Shares Outstanding (Mil.): 1,326.97
Dividend: 2.80
Yield (%): 3.45

Financials

  SASY.PA Industry Sector
P/E (TTM): 26.18 32.64 33.19
EPS (TTM): 3.10 -- --
ROI: 5.31 18.40 17.65
ROE: 7.69 19.06 18.46
Search Stocks

Sanofi, Regeneron start Phase 3 trial of dupilumab in eczema

PARIS, Oct 20 - French drugmaker Sanofi and its U.S. partner Regeneron said on Monday they had started a Phase III clinical study of their experimental drug dupilumab in patients with atopic dermatitis.

6:18am BST

BRIEF-Ab-Biotics, Sanofi to launch a gastro-pediatric drug in Spain

* Said on Thursday it reached agreement with French Sanofi to launch a gastro-pediatric drug in Spain

17 Oct 2014

Belgium's Galapagos hires Sanofi Europe exec as new CFO

BRUSSELS, Oct 15 - Belgian biotech group Galapagos said on Wednesday that it had hired Bart Filius, vice president of Sanofi Europe, as its new chief financial officer.

15 Oct 2014

Geographic split likely for GSK mature drugs sale: sources

LONDON - GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.

14 Oct 2014

Geographic split likely for GSK mature drugs sale -sources

LONDON, Oct 14 - GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.

14 Oct 2014

Sanofi's Rotavirus vaccine enters late-stage trials

PARIS - French drugmaker Sanofi said on Tuesday an investigational vaccine designed by its Shantha Biotechnics unit to protect young children from severe diarrhea had entered late-stage clinical trials in India.

14 Oct 2014

Sanofi's Rotavirus vaccine enters late-stage trials

PARIS, Oct 14 - French drugmaker Sanofi said on Tuesday an investigational vaccine designed by its Shantha Biotechnics unit to protect young children from severe diarrhoea had entered late-stage clinical trials in India.

14 Oct 2014

Sanofi French head Lajoux to leave at end-2014

PARIS - Sanofi's head of France, Christian Lajoux, plans to leave at the end of the year after 21 years with the drug making company, Chief Executive Chris Viehbacher said in a message to staff.

02 Oct 2014

Sanofi French head Lajoux to leave at end-2014

PARIS, Oct 2 - Sanofi's head of France, Christian Lajoux, plans to leave at the end of the year after 21 years with the drug making company, Chief Executive Chris Viehbacher said in a message to staff.

02 Oct 2014

Sanofi-Regeneron drug has positive trial results in chronic sinusitis

PARIS - An experimental drug from Sanofi and Regeneron significantly reduced congestion in in a mid-stage trial on patients with chronic sinusitis with nasal polyps, a condition poorly controlled by existing drugs, the companies said on Tuesday.

30 Sep 2014

Earnings vs. Estimates

Search Stocks